Astrazeneca PLC 6-K, filed Jan 6, 2020
Astrazeneca PLC (AZN)
6-K
2020-01-06
For: 2020-01-06
View Original
Added on
April 02, 2026
About this 6-K
Astrazeneca PLC filed this 6-K on January 6, 2020.
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of January
2020
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Lokelma approved in
China for the treatment of adult patients with
hyperkalaemia
6 January 2020 07:00 GMT
Lokelma approved in China for the
treatment
of adult patients with hyperkalaemia
Patients in China will benefit from Lokelma's
rapid reduction
of potassium in the blood and the sustained treatment
effect
AstraZeneca's Lokelma (sodium zirconium cyclosilicate) has been
approved in China for the treatment of adult patients with
hyperkalaemia (elevated levels of potassium in the
blood).
The approval by the National Medical Products Administration (NMPA)
was based on positive results from the
extensive Lokelma clinical trial programme and a
pharmacodynamic study in China which showed that patients receiving
Lokelma experienced a significant, rapid and sustained reduction of
potassium in the blood.
In 2019, the NMPA included Lokelma on the Accelerated Approval list of
"Overseas New Drugs in Clinical Urgent Needs for China",
recognising the significant unmet need for effective medicines
treating hyperkalaemia.
Mene Pangalos, Executive Vice President, BioPharmaceuticals
R&D, said: "This approval marks an important milestone for more
than two million patients in China who suffer from
hyperkalaemia. Lokelma will offer the opportunity for patients and
physicians to achieve long-term disease control and potentially
reduce the risk of acute episodes, which can have serious, even
life-threatening consequences."
The Lokelma clinical trials programme includes three
double-blinded, placebo-controlled trials and one open-label trial,
where patients with hyperkalaemia were treated for up to 12 months.
These trials showed that for patients
receiving Lokelma, the median time to achieving normal
potassium levels in the blood was 2.2 hours, with 98% achieving
normal levels within 48 hours from baseline.1-3 Lokelma also
demonstrated a rapid reduction of potassium in the blood as early
as one hour with one dose and a sustained treatment effect for up
to one year.1,2,4 Lokelma was
well tolerated, with few serious adverse events.2
Lokelma is approved in the
US, the EU and Canada for the treatment of hyperkalaemia. It is
undergoing separate regulatory review in Japan, with a decision
expected in the first half of 2020.
Hyperkalaemia
Hyperkalaemia is characterised by high levels of potassium in the
blood (generally classified as >5mmol/l).1 The risk
of hyperkalaemia increases significantly for patients with chronic
kidney disease (CKD) and for those who take common medications for
heart failure (HF), such as RAAS inhibitors, which can increase
potassium in the blood. Hyperkalaemia occurs in 23% to 47% of
patients with CKD and/or HF, with an estimated 200 million and 64
million people, respectively, living with each condition
worldwide.5-7 Hyperkalaemia
may lead to cardiac arrest and death, with mortality being up to
30% in patients with severe hyperkalaemia, if not treated
rapidly.8
Lokelma
Lokelma is an insoluble,
non-absorbed sodium zirconium silicate, formulated as a powder for
oral suspension, that acts as a highly selective potassium-removing
medicine. It is administered orally, is odourless, tasteless and
stable at room temperature. It has been evaluated in three
double-blinded, placebo-controlled trials and in one 12-month
open-label trial in patients with
hyperkalaemia.
AstraZeneca in CVRM
Cardiovascular, Renal and Metabolism (CVRM) together forms one of
AstraZeneca's three therapy areas and is a key growth driver for
the Company. By following the science to understand more clearly
the underlying links between the heart, kidneys and pancreas,
AstraZeneca is investing in a portfolio of medicines to protect
organs and improve outcomes by slowing disease progression,
reducing risks and tackling co-morbidities. The Company's ambition
is to modify or halt the natural course of CVRM diseases and
potentially regenerate organs and restore function, by continuing
to deliver transformative science that improves treatment practices
and cardiovascular health for millions of patients
worldwide.
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three therapy areas -
Oncology, Cardiovascular, Renal and Metabolism, and Respiratory.
AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. Please
visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
|
Media
Relations
|
|
|
|
Gonzalo
Viña
|
|
+44 203
749 5916
|
|
Rob
Skelding
|
Oncology
|
+44 203
749 5821
|
|
Rebecca
Einhorn
|
Oncology
|
+1 301
518 4122
|
|
Matt
Kent
|
BioPharmaceuticals
|
+44 203
749 5906
|
|
Angela
Fiorin
|
BioPharmaceuticals
|
+44 122
334 4690
|
|
Jennifer
Hursit
|
Other
|
+44
203 749 5762
|
|
Christina Malmberg
Hägerstrand
|
Sweden
|
+46 8 552 53 106
|
|
Michele
Meixell
|
US
|
+1 302
885 2677
|
|
|
|
|
|
Investor
Relations
|
|
|
|
Thomas
Kudsk Larsen
|
|
+44 203
749 5712
|
|
Henry
Wheeler
|
Oncology
|
+44 203
749 5797
|
|
Christer
Gruvris
|
BioPharmaceuticals
(Cardiovascular, Metabolism)
|
+44 203
749 5711
|
|
Nick
Stone
|
BioPharmaceuticals
(Renal) Environmental, Social and Governance
|
+44 203
749 5716
|
|
Josie
Afolabi
|
BioPharmaceuticals
(Respiratory)
Other
medicines
|
+44 203
749 5631
|
|
Craig
Marks
|
Finance
Fixed
income
|
+44
7881 615 764
|
|
Jennifer
Kretzmann
|
Corporate
access
Retail
investors
|
+44 203
749 5824
|
|
US
toll-free
|
|
+1 866
381 72 77
|
References
1.
AstraZeneca. Lokelma Prescribing Information. December
2019.
2. Fishbane
S, et
al. Long-term Efficacy and
Safety of Sodium Zirconium Cyclosilicate for Hyperkalemia: A
12-Month, Open-Label, Phase 3 Study. Clin J Am Soc
Nephrol. 2019 Jun
7;14(6):798-809.
3.
National Kidney Foundation. Clinical Update on Hyperkalemia. 2014.
Accessed 17 December 2019.
https://www.kidney.org/sites/default/files/02-10-6785_HBE_Hyperkalemia_Bulletin.pdf
4. Ash S, et al. A Phase 2 Study on the Treatment of Hyperkalemia
in Patients with Chronic Kidney Disease Suggests that the Selective
Potassium Trap, ZS-9, is Safe and
Efficient. Kidney Int. 2015; 88, 404-411.
5. Latts et al. Hyperkalemia Is Prevalent in Patients with
Cardiorenal Comorbidities. Presented at the ISPOR 20th Annual
International Meeting, May 16-20, 2015, Philadelphia,
PA.
6. Ojo, A. Addressing the Global
Burden of Chronic Kidney Disease Through Clinical and Translational
Research. Trans Am Clin Climatol
Assoc. 2014;
125:229-246.
7. Vos T, et al. Global, Regional, and National Incidence,
Prevalence, and Years Lived with Disability for 328 Diseases and
Injuries for 195 Countries, 1990-2016: A Systematic Analysis for
the Global Burden of Disease Study 2016. The Lancet. 2017; 390:1211-59.
8. Dunn J, et al. The burden of hyperkalaemia in patients with
cardiovascular and renal disease. Am J Manag
Care. 2015;21(15
Suppl)307-15.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date:
6 January
2020
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|